Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

1.6K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights on Endothelial Injury.

Cell biochemistry and function·2026
Same author

Octreotide Counteracts IFN-γ-Induced Endothelial Inflammation.

Journal of biochemical and molecular toxicology·2026
Same author

Author Correction: Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation.

Nature communications·2026
Same author

Ceapin-A7 counteracts the protective effects of Lanreotide in endothelial cells.

Aspects of molecular medicine·2026
Same author

Synthetic somatostatin analogs ameliorate endothelial injury due to hydrochloric acid treatment.

Environmental toxicology and pharmacology·2026
Same author

Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation.

Nature communications·2026
Same journal

Developmental maturation of intestinal junctional complexes in preterm infants.

Tissue barriers·2026
Same journal

Inflammation and epidermal barrier integrity, decline, and restoration: It's time to rouse the "guardians at the gate".

Tissue barriers·2026
Same journal

Involvement of vimentin intermediate filaments in overcoming tissue barriers during cancer cell dissemination.

Tissue barriers·2026
Same journal

Mutational signatures in blood-brain barrier: mechanisms, computational insights, and clinical applications in precision oncology.

Tissue barriers·2026
Same journal

Integrated transcriptomic and functional characterization of Claudin-1 reveals its oncogenic and immunomodulatory roles in pancreatic ductal adenocarcinoma.

Tissue barriers·2026
Same journal

Occludin deficiency is associated with developmental impairment, locomotor dysfunction, and social deficiencies.

Tissue barriers·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Isolation of Lung Retinoid-Containing Cells by Cell Sorting
07:47

Isolation of Lung Retinoid-Containing Cells by Cell Sorting

Published on: April 11, 2025

642

GHRH antagonists support lung endothelial barrier function.

Mohammad A Uddin1, Mohammad S Akhter1, Sitanshu S Singh1

  • 1School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA, USA.

Tissue Barriers
|October 4, 2019
PubMed
Summary
This summary is machine-generated.

Growth Hormone-Releasing Hormone (GHRH) antagonists reduce inflammation and improve endothelial barrier integrity. These findings suggest GHRH antagonists may treat respiratory conditions like Acute Respiratory Distress Syndrome (ARDS).

Keywords:
InflammationP53endothelial function

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.3K
Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

15.9K

Related Experiment Videos

Last Updated: Jan 6, 2026

Isolation of Lung Retinoid-Containing Cells by Cell Sorting
07:47

Isolation of Lung Retinoid-Containing Cells by Cell Sorting

Published on: April 11, 2025

642
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.3K
Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

15.9K

Area of Science:

  • Vascular Biology
  • Endocrinology
  • Oncology

Background:

  • Growth Hormone-Releasing Hormone (GHRH) influences growth hormone release and has roles in cancer.
  • GHRH's impact on endothelial permeability and inflammation is not fully understood.

Purpose of the Study:

  • To investigate the effects of GHRH and its analogs on endothelial permeability in bovine pulmonary arterial cells.
  • To explore the anti-inflammatory potential of GHRH antagonists in the vasculature.

Main Methods:

  • Utilized bovine pulmonary arterial cells to study GHRH, its agonists, and antagonists.
  • Assessed intracellular pathway activation (MLC2, ERK1/2, JAK2/STAT3, P53, pAMPK) and transendothelial electrical resistance.

Main Results:

  • GHRH antagonists suppressed MLC2, ERK1/2, and JAK2/STAT3 activation while increasing P53 and pAMPK.
  • GHRH and its agonist MR409 showed opposite effects on these pathways.
  • GHRH antagonists enhanced endothelial barrier integrity, unlike GHRH and its agonist.

Conclusions:

  • GHRH antagonists exhibit anti-inflammatory properties in the vasculature.
  • GHRH antagonists show promise as therapeutic agents for severe respiratory diseases, including Acute Respiratory Distress Syndrome (ARDS).